Abstract: A central server controls the receipt and analysis of patient medical data and patient information. The central server receives patient medical data and patient information from a remote computer. A storage system stores the received patient medical data, patient information, and the associated medical report prepared at analysis workstations at any location after analysis of the patient medical data. A processor controls access to and analysis of the patient medical data by analysis workstations and controls access to the medical report. The central server transmits the patient medical data to and receives the associated medical report from analysis workstations. The central server transmits the medical report associated with the patient medical data to the remote computer. Also, a method controls the acquisition and analysis of patient medical data over a network by a central server from a remote computer operably interconnected by the network with the central server.

Abstract: Measuring plasma 13-HODE is a useful maker to assess i) the severity or burden of coronary artery disease and ii) the risk of thrombotic events in patients undergoing medical and/or surgical procedures for revascularization.

Abstract: The invention is a central server configured to control the receipt and analysis of patient medical data and patient information. The central server controls access to the patient medical data by an analysis workstation that is responsive to a medical specialist. The analysis workstation analyzes the patient medical data and prepares a medical report associated with the patient medical data. The central server comprises a first communication interface for receiving patient medical data and patient information from a remote computer and for transmitting the medical report associated with the patient medical data to the remote computer. A storage system stores the received patient medical data, patient information, and the associated medical report. A processor is configured to control access to and analysis of the patient medical data by the analysis workstation and the medical specialist and is configured to control access to the medical report.

Abstract: This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperplasia and restoring vessel wall biocompatibility.

Abstract: A method of inhibiting thrombin generation and of inhibiting complement activation by using a dermatan sulfate having at least 2 sulfate groups per disaccharide obtained by chemical sulfation of native dermatan sulfate. The resulting dermatan sulfate having an average molecular weight from about 5000 to 35000 Daltons is characterized by (i) a high content of L-iduronic->4,6-di-O-sulfated N-acetyl-D-galactosamine residues, and (ii) a specific heparin cofactor II-mediated anti-thrombin activity, depending on average molecular weight, between about 25 to 125 U/mg.

Abstract: A chemorepellant compound is disclosed having a general formula ##STR1## where R.sub.1 is H or an alkyl group in the range C.sub.1 to C.sub.6, and R.sub.2 is H or an appropriate hydroxyl protecting group, and pharmaceutically acceptable salts and esters thereof. A preferred form of the compound where R.sub.1 is hydrogen and R.sub.2 is hydrogen is made by incubating linoleic acid with soyabean lipoxygenase or with cytosol associated endothelial cell derived lipoxygenase. The chemorepellant compound can be bound to a prosthetic surface via an intermediate linking species such as a protein and studies have shown that platelet adhesion onto in the vicinity of a thrombogenic surface is greatly reduced in comparison to non-chemorepellant coated surfaces.